New headquarters for BioMelbourne Network
Posted: 1 August 2024 On 1 August, BioMelbourne Network moved to our new headquarters in Southbank. Please update your records with our new address and phone number. Level 6, HWT Tower, 40 City Road Southbank VIC 3006 New…
Babies offered peanut allergy treatment program under world-first national model
Posted: 31 July 2024 Babies with peanut allergies in Australia will be offered a treatment program under a world-first model aiming to transform allergy care. Ten paediatric hospitals across five states have partnered with the National Allergy Centre of…
MRFF funds new national centre for mRNA medicines
Posted: 31 July 2024 The Commonwealth Government’s Medical Research Future Fund (MRFF) has invested $4 million into establishing Australia’s first National Centre for Biopharmaceutical Optimisation of mRNA Therapeutics (CORTx), being led by Monash University to optimise mRNA therapeutic…
Using mRNA technology to prevent cancer and treat disease
Posted: 31 July 2024 The Albanese Government is awarding more than $19 million to six research projects that use mRNA – the medical technology that underpins the Pfizer and Moderna COVID vaccines – to find vaccines to prevent…
Innovative technology shows promise toward hepatitis B treatment
Posted: 31 July 2024 Using cutting-edge CRISPR technology, researchers have successfully managed to reduce hepatitis B virus levels in the laboratory, lowering key viral markers by up to 96 per cent. This advancement paves the way for a…
Funding boosts endometriosis drug discovery efforts
Posted: 31 July 2024 A key receptor is being targeted using robotic high-throughput screening at the National Drug Discovery Centre (NDDC) to fast-track new treatments for endometriosis. Advancing endometriosis treatment research Endometriosis affects 10% of women of reproductive…
Telix Successfully Prices A$650 Million Convertible Bonds
Posted: 30 July 2024 Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully…
Cartherics Enters Agreement with Uniquest, The University of Queensland and The University of Sydney For Advancing Innovative Cardiac Cellular Therapy
Posted: 29 July 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered into a Technology Licence Agreement (TLA) with The…
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
Posted: 29 July 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the…
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 23 July 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive interim data from the ATH434-202 open-label Phase 2 clinical…
Dr Liriye Kurtovic awarded Moderna Global Fellowship 2023
Posted: 23 July 2024 Burnet Senior Research Officer Dr Liriye Kurtovic has been awarded a Moderna Global Fellowship to support her research into the development of a new malaria vaccine. The coveted fellowship supports scientists and healthcare professionals…
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
Posted: 23 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that positive feedback has been received from the US…
